By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site.
Industry: Biotechnology
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Institution %: 93.8
YTD Institution change: 2392513
InsidersInsiders %: 4.376
Insiders Purchases YTD: 112263
Insiders Sales YTD: 78532
Insiders Net YTD: 33731
Analyst RatingsTarget Price: 180.61
Overall Rating: 4.45
Strong Buys (5): 10
Buys (4): 9
Holds (3): 1
Sells (2): 0
Strong Sells (1): 0
52 Week Hi: 173.25
52 Week Low: 55.25
Beta: 0.814
50 Day MA: 140.099
200 Day MA: 125.5337
Earnings / Revenue TrendsQtr Earnings Growth YOY: 0
Qtr Revenue Growth YOY: 0.389
Forward PE:
Trailing PE: